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Introduction: Dyspnoea and peripheral oedema, caused by fluid redistribu-
tion to the lungs and/or by fluid overload, are the main causes of hospitaliza-
tion in patients with heart failure and are associated with poor outcomes.
Treatment of fluid overload should relieve symptoms and have a neutral or
favorable effect on outcomes.
Areas covered:We first consider the results obtained with furosemide adminis-
tration, which is still the mainstay of treatment of congestion in patients with
heart failure. We then discuss important shortcomings of furosemide treat-
ment, including the development of resistance and side effects (electrolyte
abnormalities, neurohormonal activation, worsening renal function), as well
as the relationship of furosemide -- and its doses -- with patient prognosis.
Finally, the results obtained with potential alternatives to furosemide
treatment, including different modalities of loop diuretic administration, com-
bined diuretic therapy, dopamine, inotropic agents, ultrafiltration, natriuretic
peptides, vasopressin and adenosine antagonists, are discussed.
Expert opinion: Relief of congestion is a major objective of heart failure treat-
ment but therapy remains based on the administration of furosemide, an
agent that is often not effective and is associated with poor outcomes. The
results of the few controlled studies aimed at the assessment of new treat-
ments to overcome resistance to furosemide and/or to protect the kidney
from its untoward effects have been mostly neutral. Better treatment of
congestion in heart failure remains a major unmet need.
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1. Introduction
The current treatment of heart failure (HF) with antagonists of the
renin--angiotensin--aldosterone (RAA) system, beta-blockers and devices, including
cardiac resynchronization therapy and implantable defibrillators, has improved the
prognosis for patients [1,2]. Treatment of episodes of acute decompensation may
seem satisfactory as dyspnoea and other symptoms have been reported to improve
in > 60 -- 70% of patients within the first hours of admission [3-6]. However, this
percentage may be much lower [7-11] when patients are selected more accurately
by using levels of natriuretic peptides as the inclusion criterion [9,11,12]. Prognosis
after a hospitalization for acute decompensation also remains poor, with mortality
and hospitalization rates of 9 -- 15% and 30 -- 45%, respectively, in the following
6 months [4,13-19]. Thus, there is room for improvement in the treatment of episodes
of fluid retention.
We discuss here the hypothesis that current treatment of fluid retention in
HF, based on the administration of loop diuretics, is unsatisfactory both with
respect to relief of congestion and to patients’ outcomes. Potential tools -- both
pharmacological and not -- to better treat congestion are then illustrated.
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2. Current clinical practice of prevention and
treatment of fluid retention in heart failure:
How much is effective? How much is good
for outcomes?
2.1 The in-hospital patient: is symptoms
improvement satisfactory?
Despite an apparent early and easy improvement in symp-
toms, many patients hospitalized for acute HF remain symp-
tomatic and with signs of congestion at discharge [20]. In the
IMPACT-HF (Initiation Management Predischarge: Process
for Assessment of Carvedilol Therapy in Heart Failure)
Trial, > 60% of patients were dyspnoeic, 30 -- 40% were in
New York Heart Association (NYHA) functional class III or
IV, and 9 -- 15% had pulmonary rales and/or peripheral
oedema at discharge [7,13]. In the ADHERE (Acute Decom-
pensated Heart Failure National Registry) database, at the
time of discharge 45% of the patients, although improved
compared to admission, were still symptomatic and approxi-
mately 70% had a weight loss of < 10 lb, despite evidence
of congestion at presentation [8].
It is probable that the high rates of response reported in
some trials [3-5] were caused by the inclusion of patients who
did not actually have HF as a cause of their symptoms.
Accordingly, lower rates of response are found when patients
are diagnosed based on more objective criteria (e.g., by
natriuretic peptide levels). In ADHERE, plasma levels of
B-type natriuretic peptide (BNP) were measured within
24 h of admission in 48,629 hospitalizations. BNP quartiles
were independently predictive of in-hospital mortality. They
were also predictive of the proportion of patients asymptom-
atic at discharge, with a decrease from 48 -- 49 to 43.6% in
the patients in the highest quartile of BNP levels on admission
(> 1730 pg/ml) [12]. The PROTECT (A Placebo-controlled
Randomized study of the selective A1 adenosine receptor
antagonist rolofylline for patients hospitalized with acute
HF and volume Overload to assess Treatment Effect on
Congestion and renal function) pilot trial excluded patients
with BNP or NT-proBNP levels < 250 and < 1000 pg/ml.
A moderate to marked improvement in dyspnoea at both
24 and 48 h by the Likert scale, as prospectively defined as
dyspnoea relief in the trial, was found in only 49.8% of the
patients [9], and a similar proportion (54%) with dyspnoea
relief was found in the much larger main PROTECT trial [21].
Even lower percentages (25%) were found in the Pre-RELAX-
AHF (Relaxin for the treatment of patients with Acute Heart
Failure) trial, in which patients were assessed at an earlier stage
(i.e., at 6, 12, and 24 h) by visual analogue scale (VAS) [11,22].
The method used for symptoms assessment is also impor-
tant, as highlighted in a recent registry. When dyspnoea was
assessed using a 7-point Likert scale, improvement occurred
early, with 58% of patients grading dyspnoea as improved
on the second day after admission and no further improve-
ment thereafter. By contrast, improvement was much more
gradual when it was assessed by a 100-point VAS, with a fur-
ther improvement from day 2 to day 7 after admission.
A similar behaviour was found with general well-being
scores [23].
2.2 The patient after discharge: have we achieved a
satisfactory prophylaxis of readmissions?
Fluid retention is the main cause of HF hospitalizations and
chronic administration of loop diuretics is therefore the main-
stay for the prevention of episodes of acute decompensa-
tion [1,2,19,20,24,25]. The implementation of a flexible diuretic
dose regimen, based on daily monitoring of body weight,
frequent contacts with medical personnel in disease-
management programs, and/or monitoring or telemonitoring
of biological parameters (right ventricular or pulmonary
artery pressures, oxygen saturation, etc.) [26-30] is one of the
major advances in the current treatment of chronic HF.
Despite this, an effective prevention of episodes of fluid reten-
tion is a long way from being achieved. Patients with HF gen-
erally present a further increase in body weight in the first
weeks after a hospitalization for acute HF, and such increase
is predictive of further rehospitalization [31].
A vulnerable phase for the further decompensation of HF
has recently been identified soon after discharge, when the
patient is confronted with changes in: the physician(s)
Article highlights.
. In patients with heart failure, dyspnoea and peripheral
oedema (caused by fluid redistribution to the lungs and
by fluid overload) are the main causes of hospitalization
and are associated with poor outcomes. Treatment of
fluid overload should relieve symptoms without any
negative effects on outcome.
. Furosemide remains the mainstay of treatment of
congestion in patients with heart failure.
. The current treatment of congestion in the patients with
heart failure is far from optimal: up to 50% of the
patients hospitalized for congestion may fail to show
relief of dyspnoea during the first days of hospitalization
and have a high event rate (death or re-hospitalization)
in the following months.
. Shortcomings of furosemide treatment include the
development of resistance and side effects (electrolyte
abnormalities, neurohormonal activation, worsening
renal function).
. Furosemide treatment, particularly at high doses, has
been associated with poor outcomes.
. Potential alternatives to furosemide include different
modalities of loop diuretic administration, combined
diuretic therapy, administration of dopamine, inotropic
agents, natriuretic peptides, vasopressin antagonists,
adenosine antagonists, and ultrafiltration. Results with
these treatments have been insufficient (dopamine,
ultrafiltration) or -- mostly -- neutral.
. Better treatment of congestion in heart failure remains a
major unmet need.
This box summarizes key points contained in the article.
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providing care, diet, modality of administration of new and
complex drug therapies, demands for more physical activity,
and new familial and social stresses [32]. Accordingly, the first
weeks after a hospitalization are associated with the highest
rate of re-hospitalizations [33,34], and early assessment and
follow-up in this phase are associated with significant
improvement in prognosis [35,36]. It is clear that more persis-
tent relief of congestion during the inpatient and the subse-
quent outpatient phase will also be effective in improving
patient outcomes.
The chronic administration of diuretics seems insuffi-
cient for the prevention of fluid retention and HF hospital-
izations. This may be related to the relative lack of efficacy
of diuretics. However, it may also be hypothesized that
diuretic treatment, although effective in the short-term,
may contribute to the activation of mechanisms, namely
the renin--angiotensin--aldosterone system [37] and the renal
adenosine system [38], leading to reduced renal function,
fluid retention and -- ultimately -- HF hospitalizations.
Consistently with this hypothesis, diuretic therapy has
been associated with worse prognosis in patients with
chronic HF.
3. Pitfalls and limitations of current diuretic
treatment in patients with heart failure
3.1 Loop diuretics and prognosis
Three retrospective analyses from the SOLVD (Studies of
Left Ventricular Dysfunction) trials suggested, for the
first time, that administration of non-potassium-sparing
diuretics -- namely furosemide -- may worsen patient out-
comes. The first study, performed on 6797 patients enrolled
in SOLVD, showed an increased risk of arrhythmic death
associated with diuretic use [relative risk (RR) 1.85,
p = 0.0001], which remained significant after adjustment for
important baseline factors (RR 1.37, p = 0.009) [39].
In a second analysis, Domanski et al. showed that treatment
with loop diuretics or thiazides was associated with an increase
both in total mortality [adjusted RR 1.28, 95% confidence
interval (CI) 1.19 -- 1.49] and HF hospitalization (adjusted
RR 1.38, 95% CI 1.11 -- 1.71) [40]. By contrast, treatment
with a potassium-sparing diuretic, alone or in combination
with the other diuretics, was associated with a reduction in
the risk of death or hospitalizations [40]. This protective
effect of potassium-sparing diuretics, mostly represented by
spironolactone, was probably related to protection from
hypokalaemia and aldosterone antagonism.
Knight et al. showed that diuretic use was an independent
predictor of decreased kidney function in the patients studied
in SOLVD, thus showing a third mechanism, in addition to
electrolyte disturbances and neurohormonal activation, by
which loop diuretics may worsen patients’ prognosis [41].
These data were confirmed by a retrospective analysis
of 7788 patients included in the Digitalis Investigation Group
(DIG) trial. Diuretic therapy was associated with an increase in
all-cause mortality (RR 1.31; 95% CI 1.11 -- 1.55; p = 0.002)
and HF hospitalizations (RR 1.37; 95% CI 1.13 -- 1.65;
p = 0.001), which were independent from concomitant varia-
bles, including those related to severity of HF and concomitant
treatment [42]. This study represents a further step forward,
compared to the SOLVD analyses. First, it used propensity
score methods of multivariable analysis, with adjustment for
many variables, more than what it was possible in the SOLVD
analyses. Second, > 90% of the patients were also treated with
an ACE-inhibitor and about 80% were in NYHA class I and II.
These data show that ACE inhibitors may not fully protect
from the untoward effects of diuretics and diuretics may have
unfavourable effects also at the early stages of disease progres-
sion. Similar results were obtained in other multivariable
analyses of the same trial [43,44].
3.2 Clinical significance of furosemide dose
A role of diuretic therapy is further suggested by studies show-
ing the independent prognostic value of the doses of loop
diuretic. The administration of high doses of furosemide has
been associated with increased mortality in patients with
advanced HF [45-47], elderly patients [48] and in patients hospi-
talized for acute decompensation of HF [49,50]. These relations
remained significant after adjustment for other variables at
multivariable analyses, suggesting that high doses of furosemide
may have a role as a cause of the poor outcomes of HF patients.
One important exception to these multivariable analyses was
the study by Mielniczuk et al. [47], which showed that diuretic
dose was no longer a significant determinant of prognosis
when clinical stability was taken into account, thus suggesting
that furosemide dose is more a marker than a cause of instabil-
ity. The dose of furosemide is included in a prognostic model
to predict mortality in patients with HF [51]. Administration
of high doses is also independently associated to an increased
risk of worsening renal function [41,52,53], an event with known
prognostic role [54,55].
All these data are, however, based on retrospective analy-
ses. A prospective trial comparing a strategy based on low
doses of i.v. furosemide with one based on high doses of
furosemide for the treatment of acutely decompensated
chronic HF was, therefore, extremely necessary [55]. Low-
dose i.v. furosemide was defined as the same dose the
patients were receiving orally, before hospital admission,
whereas high-dose furosemide was 2.5 the usual oral dose.
Treatment with high doses of diuretics was associated with
higher serum creatinine levels and with a slight and non-
significantly greater proportion of patients who developed
worsening renal function. However, the intensified diuretic
regimen was also associated with a better response of dys-
pnoea, as assessed by area under the curve (AUC) of VAS,
and with a numerically lower rate of events (death, rehospi-
talizations or visits to the emergency department) [56]. These
last data suggest that an increase in diuretic dose may actu-
ally have beneficial effects when used in patients with
fluid overload [57].
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How can we therefore reconcile studies showing an
increased mortality with higher furosemide doses with these
last studies actually showing better symptoms relief and, to
some extent, short-term outcomes with intensified diuretic
treatment? The key issue is probably represented by the
patient’s fluid status and the difficulties in accurately estimat-
ing this. When diuretic therapy is administered at excessive
doses it may cause fluid contraction with further neurohor-
monal activation and HF progression. By contrast, when it
is administered at insufficient doses, persistent fluid overload
and congestion may cause persistent symptoms, further dete-
rioration in renal function, through the effects of increased
pressure in the renal veins, and neurohormonal activation
through the effects of increased myocardial stress. These
observations may also explain the seemingly unexpected ben-
eficial effects of sodium loading in patients undergoing
diuretic treatment for acute HF or, even chronically, the
favorable effects of diets with a normal to high sodium
content in patients on chronic furosemide therapy [57,58].
3.3 Potential limitations and untoward effects of
loop diuretics in patients with heart failure
Mechanisms activated by loop diuretics treatment and which
may have unfavourable effects on the prognosis of patients
with HF include electrolyte abnormalities, neurohormonal
activation and worsening renal function. All these untoward
effects can be magnified by resistance to loop diuretics.
Resistance to furosemide consists of a progressive loss of
sensitivity to its administration so that increasing doses are
necessary to obtain diuresis and natriuresis; peak response to
maximal doses is also reduced. The mechanisms to resistance
to loop diuretics (namely, furosemide) in patients with HF are
multiple and hence treatment may vary. They have been thor-
oughly examined in a recent reviews [57,59,60] and are outlined
in Table 1.
Electrolyte abnormalities associated with furosemide
administration include hypokalaemia and hypomagnesaemia.
Their mechanisms and clinical significance have been previ-
ously described [61]. It is likely that the beneficial effects on
prognosis of potassium-sparing diuretics are partially related
to their effects on serum potassium levels.
Neurohormonal activation occurs in all patients with
HF, even if untreated [62]. Further activation has been
shown after both acute and chronic furosemide administra-
tion. Initial studies showed an elevation of plasma renin
activity and of plasma levels of aldosterone, vasopressin and
norepinephrine after the initiation of furosemide treat-
ment [63,64]. In another study, neurohormonal activation
after bolus administration of intravenous furosemide, 1.3 ±
0.6 mg/kg body weight, was attended by peripheral vaso-
constriction with a decrease in the stroke volume index and
an increase in left ventricular filling pressure and raised pul-
monary artery pressures. Neurohormonal activation and
peripheral vasoconstriction were followed after 3.5 h by
the expected diuresis and fall in left ventricular filling
pressure [63]. In 1990, the analysis of plasma hormone levels
in the patients enrolled in the SOLVD trials confirmed the
relationship between diuretic therapy and neurohormonal
activation with only the patients on diuretic therapy showing
an increase in plasma renin activity, compared to normal
subjects, among those enrolled in the SOLVD Prevention
trial [37]. Neurohormonal activation may contribute to
diuretic resistance and to HF progression as shown in exper-
imental models [65]. Interestingly, neurohormonal activation
has not been shown after fluid removal with ultrafiltration,
compared with standard diuretic therapy [66,67].
A third untoward effect of furosemide administration is
worsening renal function. In addition to neurohormonal acti-
vation, furosemide may contribute to the deterioration of
renal function through a local mechanism, the so-called tubu-
loglomerular feedback [38]. The increased delivery of sodium
at the level of the distal tubule of the nephron is sensed by
the juxtaglomerular cells of the macula densa with a secondary
constriction of the glomerular afferent arteriole causing a
decline in the glomerular filtration rate and, ultimately, of
sodium excretion. Tubuloglomerular feedback is therefore a
mechanism ideally aimed at avoiding excessive sodium loss
as well as reducing kidney oxygen consumption.
As adenosine is the mediator of the tubuloglomerular feed-
back, research has recently focused on the administration of
adenosine A1-receptor antagonists to maintain renal func-
tion and enhance diuresis in patients hospitalized for acutely
decompensated HF. Data from large randomized trials
have not, however, proven the hypothesis that adenosine
A1-receptor antagonism may have beneficial effects on renal
function (see below).
4. How can the treatment of congestion be
improved?
4.1 Other loop diuretics
The available loop diuretics include bumetanide, ethacrynic
acid, furosemide and torasemide; furosemide is used in by
far the largest proportion of patients with HF. The main dif-
ference between loop diuretics lies mostly in their pharmaco-
kinetics, rather than their efficacy [68]. Between 80 and 100%
of the oral doses of bumetanide or torasemide are absorbed
by the gut, compared with only 50% of an oral dose of furo-
semide. Hence, switching from an intravenous to an oral
dose of bumetanide or torsemide does not require significant
dose adjustments. However, torasemide seems to have its
greatest effects at a dose of 50 mg (100 mg in patients with
renal insufficiency) and more frequent administrations,
rather than an increase in the dose, have been recommended
in diuretic resistant patients [69]. Although torasemide has
been associated with better outcomes, less hypokalaemia
and favorable effects on left ventricular remodeling in
some studies [67,70], these data need to be confirmed by
large, prospective, randomized trials, which have not yet
been performed.
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4.2 Combination with thiazide diuretics
Three options are considered in the recent guidelines when
diuresis is inadequate to relieve congestion [2]: i) administration
of higher doses of loop diuretics; ii) continuous infusion of a
loop diuretic; and iii) addition of a second diuretic (such as a
spironolactone, a thiazide or metolazone) (Figure 1).
Continuous infusion of the loop diuretic has the advantage
that it may avoid rebound reabsorption of sodium occurring
when blood levels of the diuretic are low and may reduce
the risks of ototoxicity. However, it did not prove to be as
effective as the administration of furosemide boluses in a
recent prospective randomized trial [57].
When not contraindicated, spironolactone should always
be administered to patients with NYHA class III or IV HF,
not because of its diuretic effects but because of its beneficial
effects on outcomes [1,2]. Concomitant administration of a
thiazide diuretic is therefore potentially indicated in patients
with persistent fluid overload despite the administration of
high doses of loop diuretics and on neurohormonal antago-
nists, when tolerated, including renin, angiotensin and
aldosterone antagonists.
4.3 Dopamine
When administered at low doses, dopamine may rather selec-
tively improve renal blood flow through its action on dopamine
1 (DA1) receptors. This effect has also been demonstrated in
small study groups of patients with HF [71,72]. However, the
effects of dopamine administration, both with respect to mor-
tality and to the prevention of renal replacement therapy,
have been neutral both in controlled trials and in meta-
analyses [73,74]. There is no evidence to recommend dopamine
administration for the protection of renal function in patients
with fluid overload and need of diuretic treatment.
4.4 Inotropic agents
Renal dysfunction is related both to low cardiac output
with renal hypoperfusion and to increased intrabdominal
pressure, central venous pressure and hence renal venous
pressure in patients with HF [75,76]. Renal dysfunction
may therefore be secondary to a severe haemodynamic
impairment and inotropic therapy may -- theoretically --
be indicated to improve systolic function. Accordingly,
recent data have shown an improvement in renal func-
tion after the administration of the inotropic agent
levosimendan. However, these data were obtained in small,
single-centre trials and need confirmation by larger stud-
ies [77]. Importantly, renal dysfunction also occurs in
patients with HF and preserved left ventricular ejection
fraction, a condition in which increased renal venous pres-
sure and intraglomerular pressure, but not low cardiac out-
put, are probably the main determinants. Inotropic agents
cannot be of help in this condition.
4.5 Vasopressin antagonists
Patients with advanced HF have an activation of vasopressin
release. Vasopressin causes water retention by its action on
the collector duct, which is mediated by V1 receptors activa-
tion. The administration of antagonists of the vasopressin
type 2 receptors is associated with increased diuresis and
aquaresis in normal subjects and in patients with HF.
Hyponatremia, an abnormality caused by vasopressin activa-
tion, is also corrected by the administration of vasopressin
antagonists [78,79].
The effects of the selective vasopressinV1 receptors antagonist
tolvaptan on mortality, hospitalizations and on the symptoms
and signs of HF (dyspnoea, body weight, oedema) were assessed
in 4133 patients in the EVEREST trial [4,80]. Compared with
Table 1. Causes of resistance to furosemide.
Cause Mechanism Treatment
Excessive dietary sodium "tubular sodium load Sodium restriction
Gut congestion Furosemide malabsorption Switch to torasemide/Start i.v. loop diuretic infusion
Chronic renal dysfunction #Glomerular filtration rate Stop NSAIDs/#dose or withdraw ACEi/ARBs/
Consider hemofiltration
#cardiac output
"renal venous pressure
#Glomerular filtration rate Add Inotropic agents/hemodynamic support
Diuretic induced nephron
hyperfunction: post-diuretic
effect and braking effect
"proximal tubule and loop of
Henle sodium absorption
"diuretic dose/use multiple diuretic daily doses
or continuous i.v. infusion
Diuretic induced nephron
hypertrophy
Distal tubule cell hypertrophy:
"sodium absorption
Combination of loop diuretics with thiazide diuretics
Renin- angiotensin activation "proximal and distal tubule
sodium absorption
Renal hypoperfusion
Add ACEi/ARBs
Aldosterone activation "distal tubule sodium/potassium
exchange
Add aldosterone antagonist
Vasopressin activation Free water retention at the distal
tubule and collector duct
Water restriction/ add vasopressin antagonist
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placebo, the administration of tolvaptan was associated with a
greater reduction in body weight and with an improvement in
dyspnoea, but with no change in outcomes. It may be that the
lack of effects on outcomes is related to the mechanism of action
of vasopressin antagonists, causing an increased water excretion
but no sodium loss while patients with HF primarily have
sodium retention. The drug effects may be greater in patients
with greater activation of the vasopressin system, as shown by
hyponatremia, which was, however, present only in small
percentage of the patients enrolled in EVEREST.
Based on the data of randomized controlled trials, the role
of vasopressin antagonists seems limited to the patients with
hyponatremia rather than being generally applicable for the
treatment of fluid retention in patients with HF. Further trials
are, however, either ongoing or will start soon.
4.6 Ultrafiltration
Unlike vasopressin antagonists, ultrafiltration can rapidly and
predictably remove extracellular and intravasal fluid volume,
allowing loss of an isotonic fluid (e.g., water and sodium).
As patients with HF have an activation of primarily sodium-
retentive mechanisms, isotonic fluid loss, as achieved by
ultrafiltration, may be a better tool for the treatment of
congestion [81,82].
Ultrafiltration has been compared with standard diuretic
treatment in a few randomized trials involving a limited
number of patients [83]. In the only reasonably large multi-
centre, controlled trial accomplished to date, which compared
ultrafiltration with standard diuretic treatment in 200 patients
with HF and fluid overload, ultrafiltration was associated
with no difference in symptom improvement, and with a
slight increase in serum creatinine and a reduction in the
rehospitalization rates after discharge [84].
4.7 Antagonists of the
renin--angiotensin--aldosterone system
Antagonists of the RAA system act by antagonizing some of
the untoward effects of diuretic treatment, namely neuro-
hormonal activation and the consequent decline in renal
function, diuretic resistance, electrolyte abnormalities and
progression of cardiac dysfunction. Unfortunately, patients
with diuretic resistance and advanced HF also frequently
show intolerance to the hemodynamic and renal effects of
RAA antagonists [85].
4.8 Adenosine receptor antagonists
Stimulation of adenosine A1 receptors in the kidney is associ-
ated with enhanced reuptake of water and sodium at the level
of the distal tubule and collector duct, and with afferent
glomerular arteriole constriction with reduction in glomerular
filtration rate and diuresis. Both these actions can be regarded
as part of the general mechanism of action of adenosine, which
HF patient with symptoms and/or signs of congestion
Add or ↑ dose of furosemide (or torasemide)
O2 or non-invasive ventilation if O2 saturation < 95%
SBP < 100 mmHg, LVSD, signs
of hypoperfusion, renal or
hepatic damage
Add inotrope and/or dopamine
Persistent congestion Congestion relief
Pre- and post-discharge assessment:
-  Markers of congestion
-  Optimize treatment: ACEi/ARBs,
    betablockers, aldosterone antagonists,
    CRT, ICD...
Add a vasodilator
SBP ≥ 100 mmHg
•  ↑ dose/multiple
    administrations or continuous
    infusion of loop diuretic
•  Add thiazide-type diuretic
•  Consider vasopressin
   antagonist
•  Consider PAC
•  Consider mechanical support
Figure 1. A treatment algorithm of congestion based on systolic blood pressure in patients with acute heart failure.
CRT: Cardiac resynchronization therapy; ICD: Implantable cardioverter defibrillator; PAC: Pulmonary artery catheterization; SBP: Systolic blood pressure.
Can we improve the treatment of congestion in heart failure?
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acts as a mediator, causing oxygen and energy sparing in the
different organs and tissues. In the kidney, glomerular filtration
is actually the main cause of oxygen consumption [38].
The release of adenosine is enhanced by increased sodium
delivery to the distal tubule, where it is sensed by the cells in
the macula densa, which stimulate adenosine release by the jux-
taglomerular cells. Adenosine therefore acts as a feedback mech-
anism to avoid excessive natriuresis. In the setting of acute HF in
patients undergoing intensified diuretic treatment, generally by
furosemide administration, adenosine release has the effect of
reducing glomerular filtration rate and of limiting the natriuretic
response to the furosemide administration. This is the rationale
for the administration of adenosine A1 receptor antagonists,
combined with furosemide treatment, to enhance the diuretic
and saluretic response to furosemide administration and
preserve -- or improve -- renal function. Many, relatively small,
controlled studies had confirmed this hypothesis, showing that
the administration of adenosine A1 receptor antagonists was
associated with increased diuresis and improvement in renal
function, assessed either through serum creatinine levels and/or
glomerular filtration rate in patients with advanced HF [86,87].
It was on this basis that the Placebo-controlled Randomized
Study of the Selective A1 Adenosine Receptor Antagonist
Rolofylline for Patients Hospitalized with Acute Decompen-
sated Heart Failure and Volume Overload to Assess Treatment
Effect on Congestion and Renal FuncTion (PROTECT) trial
was designed [21,88]. In this trial, for the first time, renal func-
tion was included among the components of the primary
end-point and, as renal protection was considered a primary
mechanism of action of the drug, the hypothesis that renal pro-
tection could be associated with an improvement in outcomes
was tested. Unfortunately, the results of the trial were neutral,
both with respect of the primary end-point, including dyspnoea
relief combined with the absence of worsening HF at 1 week
and worsening renal function at 7 and 14 days, and with
respect to the pre-specified secondary outcomes of death from
any cause or rehospitalization for cardiovascular or renal causes
by day 60 and the proportion of patients with persistent renal
impairment. Paradoxically and unexpectedly, the administra-
tion of the study drug, the adenosine A1 antagonist rolofylline,
was not associated with favorable effects on renal outcomes,
although dyspnoea was slightly improved. These results can
be interpreted as showing that changes in serum creatinine
levels, the variable used to assess renal function in this study,
may have different and often opposite causes. An increase in
serum creatinine may, in fact, be caused either by overdiuresis
with contraction of the effective plasma volume and renal
hypoperfusion (so-called vasomotor nephropathy) [24] or by
an organic renal damage eventually leading to end-stage renal
failure, hemofiltration or dialysis, an event occurring in only
in 0.9 and 0.4% of the patients assigned to placebo and
rolofylline, respectively, in the PROTECT trial.
Central nervous system adenosine receptors increase the
threshold for seizures. Unlike previous studies, rolofylline
was associated with an increased risk of seizures in PROTECT
and this, in addition to the neutral effect on the primary end-
point, resulted in discontinuation of any further development
of the drug by the sponsoring company [86].
5. Conclusions
Treatment and prevention of fluid overload in patients with
HF remain based on the administration of loop diuretics.
However, the efficacy of these agents may decrease and they
may be associated with neurohormonal activation, electrolyte
abnormalities and worsening renal function. There is a need
of further interventions to treat congestion. Dopamine and
inotropic agents are often administered to patients with per-
sistent fluid overload and renal dysfunction based on the
observation that the latter may be secondary to hemodynamic
abnormalities. A further increase in aquaresis has been shown
with vasopressin antagonists, and in diuresis and saluresis with
adenosine antagonists and ultrafiltration, respectively. In
large, multicentre studies, vasopressin antagonists had no
effects on outcome and the adenosine antagonist, rolofylline,
was associated with seizures and had a neutral effect on the
primary outcome. Uultrafiltration has been effective in hospi-
talizations, compared with standard diuretic therapy, but
these results need to be confirmed by other studies.
6. Expert opinion
Fluid overload remains the main cause of hospitalization for
the patients with HF. Its treatment is still based on loop diu-
retics, despite their limited efficacy and the fact that the use
of high doses has been associated with poorer outcomes.
New treatments have failed to improve outcomes. However,
at least in the case of adenosine A1 receptor antagonists, this
has been also related to the inclusion of changes in serum
creatinine levels as a component of the primary end-point,
in addition to the central nervous system side effects.
Serum creatinine levels tend to increase whenever the patient
undergoes excessive diuresis, a common finding with high
furosemide doses, adenosine A1-receptor antagonists and
ultrafiltration, although they are not necessarily associated
with a poorer outcome. Better assessment of dyspnoea and
better focus on meaningful end-points is important for
future research.
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